Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic

Ibrutinib revolutionized therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Real-world data on the outcome of unselected patients are still limited. We analyzed 77 R/R MCL patients receiving ibrutinib with at least one prior systemic anti-lymphoma therapy. After a median follow-up of...

Descripción completa

Detalles Bibliográficos
Autores principales: Obr, Ales, Benesova, Katerina, Janikova, Andrea, Mocikova, Heidi, Belada, David, Hruskova, Andrea, Vockova, Petra, Salek, David, Sykorova, Alice, Furst, Tomas, Malarikova, Diana, Papajik, Tomas, Trneny, Marek, Klener, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807478/
https://www.ncbi.nlm.nih.gov/pubmed/36369497
http://dx.doi.org/10.1007/s00277-022-05023-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807478/
https://www.ncbi.nlm.nih.gov/pubmed/36369497
http://dx.doi.org/10.1007/s00277-022-05023-2

Ejemplares similares